Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
There has been an explosion in interest in the utility of the blood eosinophil count as a biomarker in patients with airway disease. It is a readily accessible measure, and studies have shown a consistent positive relationship between the blood eosinophil count and the risk of exacerbations [1–6], and the extent to which this can be reduced by inhaled corticosteroids (ICS) [3–5] and anti-interleukin-5 monoclonal antibodies [6–8].
AbstractBackground: Near-patient testing (NPT) is increasingly being used in the management of chronic conditions. In COPD, NPT devices include the spirometer and saturation probe, but these do not directly guide treatment. The blood eosinophil count at a cut off of ?2% has been shown to determine which patients should receive corticosteroids for exacerbations.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
